Clinical trials: Melanoma Stage III
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms
A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS) and Overall Survival(OS), achieved by HX008 Plus Transcatheter Arterial Chemoembolization (TACE) or Temozolomide…
- Trial name
- NCT05647954
- Testing
- HX008 + TACE, Temozolomide + TACE, Pembrolizumab
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Stages III Skin Melanoma, Stages II Skin Melanoma
Efficacy of Propranolol Treatment to Prevent Melanoma Progression
Melanoma's incidence is increasing worldwide. The efforts made in melanoma screening led to an earlier detection of the primary tumour and a better prognosis, but melanoma remains an aggressive cancer when it comes to its…
- Conditions
- Stages III Skin Melanoma, Stages II Skin Melanoma, Stage IB Skin Melanoma
- Trial name
- NCT01988831
- Testing
- Propranolol hydrochloride
- Where
- Switzerland
- Volunteers
- 450 people
- Sponsor
- University Hospital, Geneva
High Risk HLA-A2+ Melanoma, Metastatic Disease
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
This study is based on the hypothesis that stimulation of the immune response against the tumor can help destroy residual tumor in melanoma patients with very high risk for disease recurrence and in patients with relatively low…
- Trial name
- NCT01861938
- Testing
- Melanoma vaccine modified to express HLA A2/4-1BB ligand
- Sponsor
- Hadassah Medical Organization
Melanoma (Skin)
Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photodynamic therapy may be effective in treating melanoma.
- Trial name
- NCT00007969
- Testing
- Detox-B adjuvant, verteporfin
- Where
- 6 sites in United States
- Sponsor
- QLT Inc.
Melanoma
A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
This is a Phase 1b, open-label, dose-escalation cohort study. The study will consist of a dose escalation assessment of the safety and tolerability of Mocetinostat administered concurrently in combination with ipilimumab and…
- Trial name
- NCT03565406
- Testing
- Mocetinostat Induction Phase + Ipilimumab + Nivolumab, Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- NYU Langone Health
Melanoma
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs".
- Trial name
- NCT06246916
- Testing
- fianlimab, cemiplimab, relatlimab+nivolumab
- Where
- 113 sites in United States, Canada
- Volunteers
- 560 people
- Sponsor
- Regeneron Pharmaceuticals
Stage IB Skin Melanoma, Stage IIA Skin Melanoma
Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy
This pilot clinical trial studies intravital microscopy in identifying tumor vessels in patients with stage IB-IIIC melanoma undergoing sentinel lymph node biopsy.
- Conditions
- Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma
- Trial name
- NCT02857374
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Melanoma
Fecal Microbiota Transplant (FMT) in Melanoma Patients
The main goal of this research study is to determine if the fecal microbiota transplant (FMT) improves the body's ability to fight your cancer.
- Trial name
- NCT03341143
- Testing
- Fecal Microbiota Transplant with Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Zarour, Hassane, MD
Melanoma (Skin)
Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00470015
- Testing
- MART-1 antigen, IL-2, gp100 antigen
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Advanced Cutaneous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy
This phase I trial tests the effect of Circadian-Optimized Light Therapy (COLT) in conjunction with standard of care tumor-infiltrating lymphocytes (TIL) therapy in treating patients with melanoma that may have spread from where…
- Conditions
- Advanced Cutaneous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma
- Trial name
- NCT07628894
- Testing
- Biospecimen Collection, Internet-Based Intervention, Medical Device Usage and Evaluation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
Recurrent Melanoma, Recurrent Renal Cell Cancer
Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery
This phase I trial is studying the side effects and best dose of recombinant interferon alfa-2b when given together with azacitidine in treating patients with stage III or stage IV melanoma or stage IV kidney cancer that cannot…
- Conditions
- Recurrent Melanoma, Recurrent Renal Cell Cancer, Stage III Melanoma, Stage IV Melanoma
- Trial name
- NCT00217542
- Testing
- recombinant interferon alfa-2b, amifostine/azacitidine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
The purpose of this study is to determine the safety and tolerability of treatment with BMS-936558 (MDX-1106) in combination with Ipilimumab (BMS-734016) when given at the same time or as a sequenced regimen in subjects with…
- Trial name
- NCT01024231
- Testing
- BMS-936558 (MDX1106-04), Ipilimumab
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Bristol-Myers Squibb
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002854
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Melanoma (Skin), Non-Small-Cell Lung Carcinoma
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma
From Protocol v3.0 dated 16Jun2022. This is an international, multicenter, open-label, multiple cohort, First in Human, phase 1b clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any…
- Trial name
- NCT04990479
- Testing
- GAd-PEV, MVA-PEV
- Where
- 7 sites in Belgium, Spain and 1 more
- Volunteers
- 7 people
- Sponsor
- Nouscom SRL
Head and Neck Cancer, Melanoma
Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies
Two part prospective study to: 1. investigate the feasibility of performing ultra-deep sequencing of plasma derived circulating tumor DNA (ctDNA) in individual patients with advanced solid tumors who are currently being treated…
- Trial name
- SPECIAL (NCT02724488)
- Volunteers
- 14 people
- Sponsor
- University Health Network, Toronto
Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well ipilimumab with or without bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
- Trial name
- NCT01950390
- Testing
- Bevacizumab, Ipilimumab
- Where
- 482 sites in United States
- Volunteers
- 169 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable/Metastatic Melanoma
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously.
- Trial name
- STOP-GAP (NCT02821013)
- Testing
- Intermittent PD-1 inhibitor therapy, Continuous PD-1 inhibitor therapy
- Where
- 30 sites in Australia, Canada
- Volunteers
- 614 people
- Sponsor
- Canadian Cancer Trials Group
Malignant Melanoma
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
The purpose of this study is to evaluate a specific cellular immune response in melanoma patients that have been vaccinated with a Melan-A VLP vaccine alone or in combination with different adjuvants.
- Trial name
- NCT00651703
- Testing
- CYT004-MelQbG10 + Montanide, CYT004-MelQbG10 + Montanide + Imiquimod, CYT004-MelQbG10 + Imiquimod
- Where
- 2 sites in Switzerland
- Volunteers
- 21 people
- Sponsor
- Cytos Biotechnology AG
Metastatic Melanoma
Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma
People with brain metastases from melanoma are offered different treatment options after local treatment of their brain metastases via surgery or stereotactic irradiation.
- Trial name
- WBRTMel (NCT01503827)
- Testing
- WBRT
- Where
- 23 sites in Australia, Norway and 1 more
- Volunteers
- 220 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited